Achillion Pharmaceuticals, Inc.
(NASDAQ : ACHN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 4.33%154.810.0%$1863.66m
NVAXNovavax, Inc. 4.39%231.2392.9%$1423.06m
OCGNOcugen, Inc. 36.88%10.950.0%$1213.37m
AMGNAmgen, Inc. -1.14%224.921.3%$594.80m
ILMNIllumina, Inc. -1.45%439.413.5%$530.13m
REGNRegeneron Pharmaceuticals, Inc. -0.58%450.572.7%$522.91m
VRTXVertex Pharmaceuticals, Inc. -0.20%212.551.9%$515.41m
GILDGilead Sciences, Inc. -2.21%61.401.0%$485.52m
BIIBBiogen, Inc. -1.58%272.881.7%$380.18m
BNGOBioNano Genomics, Inc. -2.89%9.730.0%$374.38m
ALXNAlexion Pharmaceuticals, Inc. -0.59%152.752.0%$371.25m
CRSPCRISPR Therapeutics AG -1.25%125.690.6%$292.02m
EXASEXACT Sciences Corp. 3.67%136.1218.4%$252.07m
SGENSeagen Inc. 0.68%151.115.8%$212.33m
VXRTVaxart, Inc. -4.67%7.150.0%$210.57m

Company Profile

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.